Clinical Trial

Trial Protocol ID USOR 23292_ART0380C001 *STAR*

Trial Description

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Danubia Hester, MD

Disease Types

Sponsors

  • Artios Pharma Limited
  • Sarah Cannon Development Innovations

ClinicalTrials.gov NCT ID

  • NCT04657068